Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 14/20 | 0.67 |
| ▸ | GCGR | P47871 | 4/20 | 0.67 |
| ▸ | NPY1R | P25929 | 1/20 | 0.66 |
| ▸ | NPY2R | P49146 | 1/20 | 0.66 |
| ▸ | NPY4R | P50391 | 1/20 | 0.66 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.66 |
| ▸ | GIPR | P48546 | 1/20 | 0.65 |
| ▸ | CCKBR | P32239 | 2/20 | 0.65 |
| ▸ | CALCA | P06881 | 2/20 | 0.65 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30932197 | 0.94 | GLP1R (0.71) | GLP1RGCGRNPY1RNPY2RNPY4R | |
| SCHEMBL30523133 | 0.94 | GLP1R (0.71) | GLP1RGCGRNPY1RNPY2RNPY4R | |
| SCHEMBL30495753 | 0.94 | NPY1R (0.70) | GLP1RGCGRNPY1RNPY2RNPY4R | |
| SCHEMBL30598194 | 0.90 | NPY1R (0.71) | GLP1RGCGRNPY1RNPY2RNPY4R | |
| SCHEMBL30598153 | 0.90 | NPY1R (0.70) | GLP1RGCGRNPY1RNPY2RNPY4R | |
| SCHEMBL30598171 | 0.90 | GLP1R (0.71) | GLP1RGCGRNPY1RNPY2RNPY4R | |
| SCHEMBL30598183 | 0.90 | NPY1R (0.70) | GLP1RGCGRNPY1RNPY2RNPY4R | |
| SCHEMBL30658239 | 0.90 | NPY1R (0.69) | GLP1RGCGRNPY1RNPY2RNPY4R | |
| SCHEMBL30598150 | 0.89 | NPY1R (0.69) | GLP1RGCGRNPY1RNPY2RNPY4R | |
| SCHEMBL31182715 | 0.89 | NPY1R (0.70) | GLP1RGCGRNPY1RNPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2347 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| EP-4732908-A2 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-3532092-B1 | IMMUNOGLOBULINS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2026-04-29 | — | — | EP | claimed |
| US-20260110698-A1 | METHODS FOR QUANTIFYING FRATAXIN ACTIVITY | LARIMAR THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-4724044-A2 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS WITH EXTRACELLULAR VESICLE COMPOSITION | Direct Biologics, LLC (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4724043-A2 | TREATMENT OF COMPLEX REGIONAL PAIN SYNDROME WITH EXTRACELLULAR VESICLE COMPOSITION | Direct Biologics, LLC (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4712959-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 2,3,4,5-TETRAHYDRO-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES AND THE USE THEREOF | Mirum Pharmaceuticals, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| EP-4698662-A2 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | AskBio Inc. (US) | 2026-02-25 | — | — | EP | claimed |
| EP-3768271-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2026-02-18 | — | — | EP | claimed |
| US-20220160728-A1 | GENE THERAPY METHODS | HOMOLOGY MEDICINES INC (US) | 2022-05-26 | — | — | US | claimed |
| US-20220160895-A1 | GENE THERAPY METHODS | HOMOLOGY MEDICINES, INC. | 2022-05-26 | — | — | US | claimed |
| WO-2022099301-A1 | IMPROVED GENE THERAPY METHODS | HOMOLOGY MEDICINES, INC. (US) | 2022-05-12 | — | — | WO | claimed |
| WO-2022099299-A1 | IMPROVED GENE THERAPY METHODS | HOMOLOGY MEDICINES, INC. (US) | 2022-05-12 | — | — | WO | claimed |
| US-20220133839-A1 | PEPTIDE ANALOGUES WITH BRANCHED AMINO ACID PROBE(S) | TXP PHARMA GMBH (CH) | 2022-05-05 | — | — | US | claimed |
| CN-108348570-B | SPEXIN-based galanin type 2 receptor agonists and uses thereof | 纽洛可科学有限公司 | 2022-05-03 | — | — | CN | claimed |
| EP-3984537-A1 | CANCER TREATMENTS USING COMBINATIONS OF TYPE 2 MEK AND ERK INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2022-04-20 | — | — | EP | claimed |
| CN-114306870-A | Device and method for regulating galanin level and neurotransmitter concentration in brain | 李彤 | 2022-04-12 | — | — | CN | claimed |
| US-20220089821-A1 | HYDROGEL-ENCAPSULATED BETA CELLS, BETA-CELL ENCAPSULATION PROCESS, AND USES THEREOF | UNIVERSITY OF WYOMING | 2022-03-24 | — | — | US | claimed |
| CN-114181315-A | Endosome escape peptide and application thereof | 清华大学 | 2022-03-15 | — | — | CN | claimed |